Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text

Medicine, Molecular Genetics, Oncology +9

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

Medicine, Oncology, Pharmacology +11

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert et al. · The Lancet Oncology · 2014 · 978 citations

Medicine, Oncology, Pharmacology +13

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Georgina V. Long, Uwe Trefzer, Michael A. Davies et al. · The Lancet Oncology · 2012 · 908 citations

Medicine, Oncology, Pharmacology +12

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

Reinhard Dummer, Simone M. Goldinger, Christian P. Turtschi et al. · European Journal of Cancer · 2013 · 286 citations

Medicine, Neurology, Oncology +15